MX389005B - Método para tratar, prevenir o reducir el riesgo de infección cutánea. - Google Patents

Método para tratar, prevenir o reducir el riesgo de infección cutánea.

Info

Publication number
MX389005B
MX389005B MX2017006319A MX2017006319A MX389005B MX 389005 B MX389005 B MX 389005B MX 2017006319 A MX2017006319 A MX 2017006319A MX 2017006319 A MX2017006319 A MX 2017006319A MX 389005 B MX389005 B MX 389005B
Authority
MX
Mexico
Prior art keywords
treating
risk
preventing
reducing
skin infection
Prior art date
Application number
MX2017006319A
Other languages
English (en)
Spanish (es)
Other versions
MX2017006319A (es
Inventor
Erin M Duffy
Original Assignee
Melinta Subsidiary Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melinta Subsidiary Corp filed Critical Melinta Subsidiary Corp
Publication of MX2017006319A publication Critical patent/MX2017006319A/es
Publication of MX389005B publication Critical patent/MX389005B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
MX2017006319A 2014-11-14 2015-11-16 Método para tratar, prevenir o reducir el riesgo de infección cutánea. MX389005B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462080212P 2014-11-14 2014-11-14
PCT/US2015/060851 WO2016077818A1 (en) 2014-11-14 2015-11-16 Method for treating, preventing, or reducing the risk of skin infection

Publications (2)

Publication Number Publication Date
MX2017006319A MX2017006319A (es) 2017-08-10
MX389005B true MX389005B (es) 2025-03-20

Family

ID=55955188

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006319A MX389005B (es) 2014-11-14 2015-11-16 Método para tratar, prevenir o reducir el riesgo de infección cutánea.

Country Status (21)

Country Link
US (1) US10471046B2 (enExample)
EP (1) EP3217974A4 (enExample)
JP (1) JP2017534654A (enExample)
KR (1) KR20170084200A (enExample)
CN (1) CN107205989A (enExample)
AR (1) AR102666A1 (enExample)
AU (1) AU2015346023A1 (enExample)
BR (1) BR112017009989A2 (enExample)
CA (1) CA2967825A1 (enExample)
CL (1) CL2017001245A1 (enExample)
CR (1) CR20170196A (enExample)
EA (1) EA201791051A1 (enExample)
HK (1) HK1244211A1 (enExample)
IL (1) IL252197A0 (enExample)
MX (1) MX389005B (enExample)
NI (1) NI201700057A (enExample)
PH (1) PH12017500887A1 (enExample)
SG (1) SG11201703856VA (enExample)
SV (1) SV2017005444A (enExample)
UY (1) UY36402A (enExample)
WO (1) WO2016077818A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3307725A1 (en) 2015-06-11 2018-04-18 Basilea Pharmaceutica International AG Efflux-pump inhibitors and therapeutic uses thereof
JP7174700B2 (ja) * 2016-12-09 2022-11-17 セルタクシー、エルエルシー ロイコトリエンａ４ヒドロラーゼの阻害剤としてのモノアミン及びモノアミン誘導体
CN107721943A (zh) * 2017-10-26 2018-02-23 沈阳药科大学 含联芳基腙结构的噁唑烷酮类化合物及其制备方法
KR20190130243A (ko) 2018-05-14 2019-11-22 (주)텔리언 트러스트 인덱스를 이용한 공유경제 시스템 및 방법
CN114051496B (zh) 2019-06-25 2023-08-04 阿米蒂比奥有限公司 将联苯基引入新型氨基烷酸的衍生物化合物及包含其的抗真菌药学组合物
CN115677679A (zh) * 2021-07-26 2023-02-03 沈阳药科大学 含联芳基腙结构的噁唑烷酮化合物及其制备方法和应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES332272A1 (es) 1965-10-20 1967-11-16 Milwaukee Chaplet & Mfg Company Inc Un dispositivo regulador de programa.
GB1185685A (en) 1966-01-11 1970-03-25 Quinoderm Ltd Method of Making Pharmaceutical Compositions
US3418055A (en) 1967-04-03 1968-12-24 Schwartzman Gilbert Pressure operated applicator and cap construction
US3410645A (en) 1967-05-08 1968-11-12 Schwartzman Gilbert Concave diaphragm applicator
US3535422A (en) 1968-03-11 1970-10-20 Stiefel Laboratories Stable benzoyl peroxide composition
US3669323A (en) 1969-12-12 1972-06-13 American Can Co One-way valve insert for collapsible dispensing containers
US4056611A (en) 1973-04-16 1977-11-01 Stiefel Laboratories, Inc. Therapeutic composition
GB1541463A (en) 1975-10-11 1979-02-28 Lion Dentifrice Co Ltd Process for prparing a multiple emulsion having a dispersing form of water-phase/oil-phase/water-phase
US4620648A (en) 1982-07-06 1986-11-04 Dab-O-Matic Corp. Pressure-responsive valve
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4985459A (en) 1984-02-08 1991-01-15 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4693623A (en) 1984-03-02 1987-09-15 Dab-O-Matic Corp. Pressure-responsive valve for an applicator
US4937370A (en) 1987-06-02 1990-06-26 The Procter & Gamble Company Novel chromophores, sunscreen compositions and methods for preventing sunburn
US4999186A (en) 1986-06-27 1991-03-12 The Procter & Gamble Company Novel sunscreen agents, sunscreen compositions and methods for preventing sunburn
US4960764A (en) 1987-03-06 1990-10-02 Richardson-Vicks Inc. Oil-in-water-in-silicone emulsion compositions
US4800197A (en) 1987-07-17 1989-01-24 Richardson-Vicks Inc. Anti-acne composition
US4891227A (en) 1988-02-02 1990-01-02 Richardson-Vicks Inc. Medicated cleansing pads
US4891228A (en) 1988-02-02 1990-01-02 Richardson-Vicks Inc. Medicated cleansing pads
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US5087445A (en) 1989-09-08 1992-02-11 Richardson-Vicks, Inc. Photoprotection compositions having reduced dermal irritation
US5073371A (en) 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5073372A (en) 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
CA2119556C (en) 1991-11-01 2004-07-06 Michael Robert Barbachyn Substituted aryl- and heteroaryl-phenyloxazolidinones
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
US6107482A (en) 1995-03-27 2000-08-22 Isis Pharmaceuticals, Inc. Nitrogenous macrocyclic compounds
DE69628466T2 (de) 1995-09-22 2004-04-01 Wakunaga Pharmaceutical Co., Ltd. Zwischenverbindungen zur Herstellung von neunen Pyridoncarbonsäurederivate oder deren Salzen
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US6413981B1 (en) * 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
MXPA02012045A (es) 2000-06-05 2003-10-15 Dong A Pharm Co Ltd Nuevos derivados de oxazolidinona y proceso para su preparacion.
US20130059774A1 (en) * 2000-08-01 2013-03-07 Mahesh Vithalbhai Patel Efflux pump inhibitors
US20030096850A1 (en) * 2001-10-11 2003-05-22 Ford Charles W. Treating infections by administration of oxazolidinones
AR043050A1 (es) 2002-09-26 2005-07-13 Rib X Pharmaceuticals Inc Compuestos heterociclicos bifuncionales y metodos para preparar y usar los mismos
KR20060002800A (ko) 2003-03-05 2006-01-09 립-엑스 파마슈티칼즈, 인크. 이관능성 헤테로시클릭 화합물, 및 그의 제조 및 사용 방법
AU2004267007C1 (en) * 2003-06-03 2010-04-29 Melinta Subsidiary Corp. Biaryl heterocyclic compounds and methods of making and using the same
WO2005012271A2 (en) 2003-07-29 2005-02-10 Rib-X Pharmaceuticals, Inc. Process for the synthesis of biaryl oxazolidinones
SI1656370T1 (sl) 2003-06-03 2012-12-31 Rib-X Pharmaceuticals, Inc. Biarilne heterociklične spojine in postopki za njihovo izdelavo in uporabo
WO2005012270A2 (en) 2003-07-29 2005-02-10 Rib-X Pharmaceuticals, Inc. Biaryl heterocyclic amines, amides, and sulfur-containing compounds and methods of making and using the same
US7129259B2 (en) 2003-12-17 2006-10-31 Rib-X Pharmaceuticals, Inc. Halogenated biaryl heterocyclic compounds and methods of making and using the same
JP2008508271A (ja) 2004-07-28 2008-03-21 リブ−エックス ファーマシューティカルズ，インコーポレイテッド ビアリール複素環式化合物ならびにその化合物を製造および使用する方法
EP2816033A1 (en) 2004-07-30 2014-12-24 Abbvie Inc. Preparation of pyridonecarboxylic acid antibacterials
MX2007004111A (es) 2004-10-08 2007-06-14 Abbott Lab Sal y formas cristalinas de la misma de un farmaco.
HRP20120502T1 (hr) 2005-04-11 2012-07-31 Abbott@Laboratories Farmaceutske smjese s poboljšanim profilom otapanja za slabo topljive lijekove
DE602006019870D1 (de) 2005-06-08 2011-03-10 Rib X Pharmaceuticals Inc Verfahren zur synthese von triazolen
US8470985B2 (en) 2005-08-24 2013-06-25 Rib-X Pharmaceuticals, Inc. Triazole compounds and methods of making and using the same
DK1934238T3 (en) 2005-08-24 2017-09-18 Melinta Therapeutics Inc TRIAZOL COMPOUNDS AND METHODS FOR THE PREPARATION AND USE OF THESE
WO2011139832A2 (en) * 2010-04-28 2011-11-10 Rib-X Pharmaceuticals, Inc. Method for treating mycobacterial infections

Also Published As

Publication number Publication date
MX2017006319A (es) 2017-08-10
CL2017001245A1 (es) 2018-02-09
AU2015346023A1 (en) 2017-06-01
EP3217974A4 (en) 2018-07-25
SV2017005444A (es) 2017-08-31
SG11201703856VA (en) 2017-06-29
HK1244211A1 (zh) 2018-08-03
EP3217974A1 (en) 2017-09-20
BR112017009989A2 (pt) 2018-01-02
UY36402A (es) 2016-06-30
PH12017500887A1 (en) 2017-11-06
AR102666A1 (es) 2017-03-15
EA201791051A1 (ru) 2018-01-31
US10471046B2 (en) 2019-11-12
CN107205989A (zh) 2017-09-26
WO2016077818A1 (en) 2016-05-19
US20160136137A1 (en) 2016-05-19
JP2017534654A (ja) 2017-11-24
CR20170196A (es) 2017-07-10
IL252197A0 (en) 2017-07-31
KR20170084200A (ko) 2017-07-19
NI201700057A (es) 2017-09-04
CA2967825A1 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
PH12017500887A1 (en) Method for treating, preventing, or reducing the risk of skin infection
CL2016002285A1 (es) Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas
MX2016009898A (es) Tratamientos para acne resistente.
IL248959A0 (en) Preparations and methods for the treatment and prevention of staphylococcus aureus infections
NI201600051A (es) Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
MX386598B (es) Compuestos antibacterianos.
BR112017004889A2 (pt) uso antibacteriano de salicilanilidas halogenadas
PH12017501646A1 (en) Antimicrobial compounds and methods of making and using the same
MX377544B (es) Composiciones topicas que comprenden un corticosteroide y un retinoide para tratar psoriasis.
BR112017000398A2 (pt) composto ou sal do mesmo, método de tratamento de uma infecção causada por dirofilaria immitis, e, kit.
MX2015016319A (es) Terapia de combinacion que comprende oxazolidinona-quinolonas para uso en el tratamiento de infecciones bacterianas.
BR112017000520A2 (pt) composto ou sal do mesmo, uso um composto ou de um sal, e, kit.
DK3432900T3 (da) Mælkesyrebakteriesammensæting til behandling af bakterielle vaginale infektioner forårsaget af gardnerella vaginalis og, hvis de forefindes, samtidige svampeinfektioner
NZ764310A (en) Antibacterial compounds
UY37245A (es) Formulaciones tópicas de compuestos heterocíclicos de biarilo y métodos de uso de estas
MX395175B (es) Compuesto heterocíclico aromático nitrogenado, método de preparación para el mismo, composición farmacéutica del mismo, y aplicación del mismo.
MX2016010699A (es) Composiciones y metodos para tratar neutropenia.
BR112016014099A2 (pt) método de tratamento de feridas
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
MX2016012623A (es) Combinacion de adapaleno y peroxido de benzoilo para tratar cicatrices de acne.
ECSP16095557A (es) Métodos para tratar infecciones
CR20160591A (es) Metodos para tratar infecciones
HK1236389A1 (en) Compositions and methods for treating and preventing staphylococcus aureus infections
CL2015001491A1 (es) Composición veterinaria tópica fungicida y antibacterial que comprende al menos un ácido dicarboxílico; y método para tratar heridas.